[Federal Register Volume 79, Number 72 (Tuesday, April 15, 2014)]
[Notices]
[Pages 21251-21252]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-08387]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Option License: Immunotherapy
Vaccine for Treating Lymphoma and Leukemia
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant to University of Texas
MD Anderson Cancer Center, of an exclusive option license to practice
the inventions embodied in the following US Patents and US Patent
Applications (and all foreign counterparts) for the continued research
and development of the inventions: US Patent Application Serial No. 13/
890,502, entitled, ``Viral Chemokine-antigen Fusion Proteins'' [HHS
Ref. No. E-194-2000/0-US-06] and in US Patent Serial No. 8,258,278 and
US Patent Application Serial No.13/587,515, both entitled ``Methods and
Compositions for the Treatment and Prevention of Cancer'' [HHS Ref.
Nos. E-271-2006/0-US-03 and E-271-2006/0-US-04, respectively]. The
patent rights in this invention have been assigned to the Government of
the United States of America.
The exclusive option license may be term-limited, the prospective
territory may be worldwide, and the field of use may be limited to:
Research, development, manufacture, and related non-commercial
use in humans for the treatment of B-cell leukemias and B-cell
lymphoma of a chemokine-tumor antigen fusion protein in which the
chemokine is viral Macrophage Inflammatory Protein 3 Alpha
(MIP3[alpha]) and the tumor antigen is the epitope of a malignant B-
cell immunoglobulin idiotype of an antibody produced by a B-cell
lymphoma.
Prior to the expiration or termination of the exclusive option license,
University of Texas M.D. Anderson Cancer Center will have the exclusive
right to amend the option license to include the right to sublicense
for commercialization.
DATES: Only written comments or applications for a license (or both)
which are received by the NIH Office of Technology Transfer on or
before April 30, 2014 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments, and other materials relating to the contemplated exclusive
option license should be directed to: Yolanda Mock Hawkins, Ph.D.,
M.B.A., Licensing and Patenting Manager, Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; Telephone: (301) 435-5170; Facsimile: (301)
402-0220; Email: [email protected].
SUPPLEMENTARY INFORMATION: This invention concerns a cancer treatment
for B-cell lymphoma comprising a vaccine that increases the ability of
a B-cell lymphoma antigen to provoke an immune response in the body. In
particular, the vaccine comprises a viral chemokine fused to a tumor
antigen and
[[Page 21252]]
is administered as either a protein or a nucleic acid.
The prospective exclusive option license, and any potential
sublicense, will comply with the terms and conditions of 35 U.S.C. 209
and 37 CFR part 404. The prospective exclusive option license, may be
granted unless the NIH receives within fifteen (15) days from the date
of this published notice written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive option license. Comments and objections
submitted to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: April 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-08387 Filed 4-14-14; 8:45 am]
BILLING CODE 4140-01-P